Uncategorized

#AAD26: Biogen declares Phase 2 lupus success for anti-BDCA2 antibody

#AAD26: Biogen declares Phase 2 lupus success for anti-BDCA2 antibody

Published

on

Biogen trumpeted new Phase 2 lupus data on Saturday for a program it hopes will become a pillar of its immunology pipeline.

The drug litifilimab improved patients’ skin lesions after 24 weeks, with 14.7% reaching …​ ​Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version